Biologics switch in psoriasis-Reference-Cited by-同舟云学术

Biologics switch in psoriasis

Published:2019-04 Issue:6 Volume:11 Page:531-541
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Wang Ting-Shun¹²³,Tsai Tsen-Fang³

Affiliation:

1. Department of Dermatology, Chung Shan Medical University Hospital, Taichung, Taiwan

2. Department of Dermatology, Chung Shan Medical University, Taichung, Taiwan

3. Department of Dermatology, National Taiwan University Hospital & National Taiwan University College of Medicine, Taipei, Taiwan

Abstract

Aim: No guidelines exist for biologic switch in psoriasis after treatment failure. Although, switching between TNF-α antagonists has been reviewed, switching information about newer biologics is limited. Materials & methods: We did a thorough systematic review from ‘PubMed’ and ‘Embase’, which includes new biologics such as IL-12/IL-23 antagonists, IL-17A antagonists and IL-23 antagonists. Results & conclusion: New biologics such as IL-17 antagonist or IL-23 antagonist show greater responses in bio-experienced patients and could even be used for patients in whom previous treatments failed.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2018-0131

Reference41 articles.

1. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study

2. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept

3. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept

4. Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting

5. Adalimumab treats psoriasis in patients previously treated with etanercept: A case series

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research trends and hotspots in biologics for plaque psoriasis: A bibliometric study from 2004 to 2023;Heliyon;2024-08

2. Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: a Danish population-based cohort study;Rheumatology;2023-08-30

3. Effectiveness and safety of ustekinumab for the treatment of psoriasis; six years of clinical experience;Journal of Dermatological Treatment;2023-08-02

4. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system;Expert Opinion on Drug Safety;2023-06-13

5. Biologics for psoriasis patients under 18 years of age: Real-world evidence from the Chinese psoriasis real world evidence research group;Frontiers in Medicine;2022-09-07